Matthew Daubresse1,2, Susan Hutfless1,2,3, Yoonsang Kim4, Rachel Kornfield4, Dima M Qato5,6, Jidong Huang4, Kay Miller7, Sherry L Emery4, G Caleb Alexander1,2,8. 1. 1 Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 2. 2 Center for Drug Safety and Effectiveness. 3. 3 Division of Gastroenterology and Hepatology, Department of Medicine, and. 4. 4 Institute for Health Research and Policy. 5. 5 Department of Pharmacy Systems, Outcomes, and Policy, College of Pharmacy, and. 6. 6 Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago, Chicago, Illinois; and. 7. 7 Truven Health Analytics, Santa Barbara, California. 8. 8 Division of General Internal Medicine, Department of Medicine, Johns Hopkins University, Baltimore, Maryland.
Abstract
RATIONALE: The United States is one of only two countries that permit direct-to-consumer advertising (DTCA) of prescription drugs, and many questions remain regarding its effects. OBJECTIVES: To quantify the association between asthma-related DTCA, pharmacy sales, and healthcare use. METHODS: This was an ecological study from 2005 through 2009 using linked data from Nielsen (DTCA television ratings), the IMS Health National Prescription Audit (pharmacy sales), and the MarketScan Commercial Claims data (healthcare use) for 75 designated market areas in the United States. We used multilevel Poisson regression to model the relationship between DTCA and rates of prescriptions and use within and across designated market areas. Main outcome measures include (1) volume of total, new, and refilled prescriptions for advertised products based on pharmacy sales; (2) prescription claims for asthma medications; and asthma-related (3) emergency department use, (4) hospitalizations, and (5) outpatient encounters among the commercially insured. MEASUREMENTS AND MAIN RESULTS: Four Food and Drug Administration-approved asthma medicines were advertised during the period examined: (1) fluticasone/salmeterol (Advair), (2) mometasone furoate (Asmanex), (3) montelukast (Singulair), and (4) budesonide/formoterol (Symbicort). After adjustment, each additional televised advertisement was associated with 2% (incident rate ratio, 1.02; 95% confidence interval, 1.01-1.03) higher pharmacy sales rate from 2005 through 2009, although this effect varied across the three consistently advertised therapies examined. Among the commercially insured, DTCA was positively and significantly associated with emergency room visits related to asthma (incident rate ratio, 1.02; 95% confidence interval, 1.01-1.04), but there was no relationship with hospitalizations or outpatient encounters. CONCLUSIONS: Among this population, DTCA was associated with higher prescription sales and asthma-related emergency department use.
RATIONALE: The United States is one of only two countries that permit direct-to-consumer advertising (DTCA) of prescription drugs, and many questions remain regarding its effects. OBJECTIVES: To quantify the association between asthma-related DTCA, pharmacy sales, and healthcare use. METHODS: This was an ecological study from 2005 through 2009 using linked data from Nielsen (DTCA television ratings), the IMS Health National Prescription Audit (pharmacy sales), and the MarketScan Commercial Claims data (healthcare use) for 75 designated market areas in the United States. We used multilevel Poisson regression to model the relationship between DTCA and rates of prescriptions and use within and across designated market areas. Main outcome measures include (1) volume of total, new, and refilled prescriptions for advertised products based on pharmacy sales; (2) prescription claims for asthma medications; and asthma-related (3) emergency department use, (4) hospitalizations, and (5) outpatient encounters among the commercially insured. MEASUREMENTS AND MAIN RESULTS: Four Food and Drug Administration-approved asthma medicines were advertised during the period examined: (1) fluticasone/salmeterol (Advair), (2) mometasone furoate (Asmanex), (3) montelukast (Singulair), and (4) budesonide/formoterol (Symbicort). After adjustment, each additional televised advertisement was associated with 2% (incident rate ratio, 1.02; 95% confidence interval, 1.01-1.03) higher pharmacy sales rate from 2005 through 2009, although this effect varied across the three consistently advertised therapies examined. Among the commercially insured, DTCA was positively and significantly associated with emergency room visits related to asthma (incident rate ratio, 1.02; 95% confidence interval, 1.01-1.04), but there was no relationship with hospitalizations or outpatient encounters. CONCLUSIONS: Among this population, DTCA was associated with higher prescription sales and asthma-related emergency department use.
Entities:
Keywords:
asthma; direct-to-consumer advertising; healthcare use
Authors: W David Bradford; Andrew N Kleit; Paul J Nietert; Terrence Steyer; Thomas McIlwain; Steven Ornstein Journal: Health Aff (Millwood) Date: 2006 Sep-Oct Impact factor: 6.301
Authors: Geoffrey K Spurling; Peter R Mansfield; Brett D Montgomery; Joel Lexchin; Jenny Doust; Noordin Othman; Agnes I Vitry Journal: PLoS Med Date: 2010-10-19 Impact factor: 11.069
Authors: George Hripcsak; Patrick B Ryan; Jon D Duke; Nigam H Shah; Rae Woong Park; Vojtech Huser; Marc A Suchard; Martijn J Schuemie; Frank J DeFalco; Adler Perotte; Juan M Banda; Christian G Reich; Lisa M Schilling; Michael E Matheny; Daniella Meeker; Nicole Pratt; David Madigan Journal: Proc Natl Acad Sci U S A Date: 2016-06-06 Impact factor: 11.205
Authors: Hsien-Yen Chang; Irene Murimi; Matthew Daubresse; Dima M Qato; Sherry L Emery; G Caleb Alexander Journal: Med Care Date: 2017-08 Impact factor: 2.983
Authors: Helen W Sullivan; Amie C O'Donoghue; Molly Lynch; Mihaela Johnson; Christine Davis; Douglas J Rupert Journal: Med Decis Making Date: 2019-10-04 Impact factor: 2.583
Authors: Matthew F Griffith; Laura C Feemster; Steven B Zeliadt; Lucas M Donovan; Laura J Spece; Edmunds M Udris; David H Au Journal: J Gen Intern Med Date: 2019-11-11 Impact factor: 5.128
Authors: Helen W Sullivan; Amie C O'Donoghue; Molly Lynch; Mihaela Johnson; Christine Davis; Jacqueline B Amoozegar; Douglas J Rupert Journal: Patient Educ Couns Date: 2021-02-13